Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
VISIPAQUE 320 vs ZEPATIER
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Iodinated nonionic radiocontrast agent that attenuates X-rays and enhances vascular and tissue contrast.
ZEPATIER is a fixed-dose combination of elbasvir, an HCV NS5A inhibitor, and grazoprevir, an HCV NS3/4A protease inhibitor. Elbasvir inhibits HCV NS5A, disrupting viral replication and assembly. Grazoprevir inhibits the HCV NS3/4A serine protease, preventing cleavage of the HCV polyprotein into mature viral proteins.
CT imaging,angiography,urography
Treatment of chronic hepatitis C virus (HCV) genotype 1 or 4 infection in adults,Treatment of chronic HCV genotype 1 or 4 infection in pediatric patients 12 years of age and older or weighing at least 30 kg
Intravascular administration: Adult dose is 50-150 m L (16-48 g iodine) intravenously as a bolus or infusion, depending on the procedure. For CT imaging, typical dose is 75-150 m L at 1-3 m L/sec.
One tablet (elbasvir 50 mg/grazoprevir 100 mg) orally once daily.
Terminal elimination half-life is approximately 2 hours in patients with normal renal function. Clinically, clearance is prolonged in renal impairment, requiring dose adjustment.
Elbasvir: terminal half-life approximately 24 hours. Grazoprevir: terminal half-life approximately 31 hours. The prolonged half-lives support once-daily dosing and allow for sustained viral suppression.
GFR <30 m L/min: Use lowest effective dose, ensure hydration, consider alternative if GFR <15 m L/min. No specific dose reduction formula; risk of contrast-induced nephropathy increases with reduced renal function.
No dose adjustment required for any degree of renal impairment including end-stage renal disease on dialysis.
None
Iodinated contrast media cross the placenta. Animal studies have not demonstrated teratogenic effects. In humans, there is no evidence of fetal harm from routine diagnostic use. However, fetal thyroid function may be transiently affected if high doses are administered near term. Use only if clearly needed.
ZEPATIER (grazoprevir/elbasvir) is contraindicated in pregnancy due to the ribavirin component in some regimens. Ribavirin is teratogenic in all trimesters, causing fetal malformations and embryolethality. Grazoprevir/elbasvir alone has no adequate human data, but animal studies show no teratogenicity. However, combination with ribavirin mandates avoidance in pregnancy.
VISIPAQUE 320 (iodixanol) is an iso-osmolar, nonionic dimeric iodinated contrast agent. It has lower nephrotoxicity risk compared to high-osmolar agents, but caution is still warranted in patients with pre-existing renal impairment (e GFR <30 m L/min). Ensure adequate hydration before and after administration. Consider prophylactic N-acetylcysteine or sodium bicarbonate in high-risk patients. Hold metformin for 48 hours post-procedure if renal function is compromised. It is contraindicated in patients with known anaphylactic reactions to iodinated contrast. Pre-medication with corticosteroids and antihistamines may be considered for at-risk patients.
ZEPATIER (elbasvir/grazoprevir) is indicated for chronic HCV genotypes 1 or 4. Prior to initiation, test for NS5A resistance-associated substitutions (RASs) in genotype 1a. In patients with genotype 1a and baseline NS5A RASs, treatment duration is 16 weeks with ribavirin. Avoid in moderate to severe hepatic impairment (Child-Pugh B or C). Monitor hepatic function closely. Coadministration with strong CYP3A4 inducers (e.g., rifampin, carbamazepine) is contraindicated. Also contraindicated with OATP1B1/3 inhibitors (e.g., cyclosporine) and certain HIV protease inhibitors (e.g., atazanavir, darunavir, lopinavir). Grazoprevir increases serum creatinine due to OATP2B1 inhibition, but this does not reflect true renal function decline.
No interactions on record
No interactions on record
VISIPAQUE 320 and ZEPATIER are distinct pharmacological agents. VISIPAQUE 320 belongs to the Radiographic Contrast Agent class and is primarily used for CT imagingangiographyurography. ZEPATIER belongs to the Direct-Acting Antiviral (HCV) class and is primarily used for Treatment of chronic hepatitis C virus (HCV) genotype 1 or 4 infection in adultsTreatment of chronic HCV genotype 1 or 4 infection in pediatric patients 12 years of age and older or weighing at least 30 kg. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. VISIPAQUE 320 carries a safety status of Category C, whereas ZEPATIER safety is classified as Category C. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Not metabolized; excreted unchanged by glomerular filtration.
Elbasvir is metabolized primarily by CYP3A. Grazoprevir is metabolized primarily by CYP3A. Mild oxidation and glucuronidation are minor pathways.
Primarily renal via glomerular filtration; approximately 95% of the dose excreted unchanged in urine within 24 hours. Biliary/fecal excretion is minimal (<1%).
Elbasvir: primarily biliary/fecal (≥90% as metabolites, <1% unchanged in urine). Grazoprevir: primarily biliary/fecal (≥90% as metabolites, <1% unchanged in urine). Renal elimination is negligible for both.
Approximately 5-10%, primarily to albumin.
Elbasvir: ≥99.9% bound, primarily to albumin and α1-acid glycoprotein. Grazoprevir: 98.8% bound, primarily to albumin and α1-acid glycoprotein.
0.2-0.3 L/kg, reflecting limited extravascular distribution consistent with high water solubility and renal excretion.
Elbasvir: apparent Vd approximately 4.5 L/kg (high, indicating extensive tissue distribution). Grazoprevir: apparent Vd approximately 19 L/kg (very high, likely due to binding to plasma proteins and tissue uptake).
Not applicable; administered intravenously (100% bioavailable) or intra-arterially. Oral bioavailability is negligible (<1%) and not clinically relevant.
Elbasvir: absolute bioavailability not determined in humans; oral absorption is high. Grazoprevir: absolute bioavailability approximately 27% after oral administration; absorption is enhanced with food (high-fat meal increases AUC by 1.5-fold).
No specific dosing adjustment required for hepatic impairment. Use caution in severe hepatic disease due to potential for hepatorenal syndrome.
Contraindicated in moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment. No dose adjustment required in mild (Child-Pugh A) hepatic impairment.
Weight-based: 1-2 m L/kg (0.32-0.64 g iodine/kg) intravenously, not to exceed 150 m L total. For pediatric CT, typical dose is 1-2 m L/kg at 1-2 m L/sec.
Not approved for use in pediatric patients; safety and efficacy not established.
Use lowest effective dose; monitor renal function and hydration status due to age-related decreased GFR. Increased risk of adverse effects (e.g., nephrotoxicity, cardiovascular events).
No dose adjustment required; however, clinical studies indicate similar safety and efficacy as in younger adults, but caution is warranted due to potential age-related comorbidities.
Risk of hepatitis B virus (HBV) reactivation in patients coinfected with HCV and HBV, which may result in fulminant hepatitis, hepatic failure, and death. Test all patients for evidence of current or prior HBV infection before initiating treatment.
No specific food interactions. However, patients receiving iodinated contrast should maintain adequate hydration. Avoid alcohol consumption due to potential dehydration. Fasting may be required for some procedures; follow specific pre-procedure dietary instructions.
ZEPATIER can be taken with or without food. No specific food restrictions are required. Grapefruit and grapefruit juice may increase exposure to grazoprevir; although not contraindicated, consider avoiding large quantities.
Iodinated contrast media are excreted into breast milk in very small amounts (less than 1% of maternal dose). The M/P ratio is low. The American College of Radiology states that breastfeeding can be continued without interruption after contrast administration.
No data on human milk excretion. M/P ratio unknown. Ribavirin accumulates in breast milk and is contraindicated during breastfeeding. Grazoprevir/elbasvir: animal studies show excretion in milk; potential for adverse effects. Avoid breastfeeding during treatment and for 7 days after last dose.
No dose adjustment required for pregnancy. Physiologic changes (increased plasma volume, increased GFR) do not necessitate dose modification. Use lowest dose necessary to achieve diagnostic quality.
No dose adjustment studies in pregnancy. ZEPATIER is not recommended during pregnancy due to ribavirin component. If inadvertently used, no specific dose adjustment; consult maternal-fetal specialist.
Inform your doctor if you have kidney problems, diabetes, or are taking metformin.,You may need to stop taking metformin for 48 hours after the procedure.,Drink plenty of water before and after the scan unless instructed otherwise.,Tell your doctor about any allergies, especially to iodine or contrast agents.,Side effects may include warmth, nausea, or a metallic taste, which usually resolve quickly.,Report any symptoms of allergic reaction such as hives, difficulty breathing, or swelling.
Take ZEPATIER exactly as prescribed, one tablet once daily with or without food.,Do not stop or skip doses without consulting your healthcare provider.,Inform your doctor of all medications you take, including over-the-counter drugs and herbal supplements, to avoid serious interactions.,Notify your healthcare provider immediately if you experience symptoms of liver problems: yellowing of skin or eyes, dark urine, pale stools, nausea, vomiting, or right upper abdominal pain.,ZEPATIER may elevate creatinine levels without reflecting kidney damage; your doctor will monitor appropriately.,If you have genotype 1a HCV, your doctor will test for specific resistance mutations to determine the correct treatment duration.,Avoid alcohol during treatment as it can exacerbate liver injury.,Use effective contraception during treatment and for 2 weeks after the last dose if you or your partner can become pregnant.